Subscribe to RSS
DOI: 10.1055/a-2781-5158
Pulmonary Artery Sarcoma: A Rare Enemy Behind the Mask of Pulmonary Embolism
Authors
Abstract
Pulmonary artery sarcoma (PAS) is a very rare and highly aggressive malignancy arising from the intimal layer of the pulmonary arteries. It commonly presents with nonspecific symptoms, often mimicking pulmonary embolism (PE), leading to treatment delays that worsen outcomes. We report a case of PAS initially managed as presumed PE in a middle-aged man. A 47-year-old man presented with intermittent right-sided chest pain, dyspnea, and fatigue following treatment for presumed pneumonia. Initial evaluation, including chest computed tomography (CT) angiography, revealed a filling defect in the right pulmonary artery, and anticoagulation was initiated for suspected PE. Six months later, the patient returned with persistent symptoms; repeat CT imaging demonstrated an unchanged intraluminal defect, an enlarged right hilar lymph node, and a right adrenal mass. Mediastinal lymph node biopsy was nondiagnostic. CT-guided biopsy of the adrenal lesion confirmed high-grade undifferentiated sarcoma. Positron emission tomography–computed tomography (PET-CT) demonstrated intense fluorodeoxyglucose (FDG) uptake in the right pulmonary artery, right hilum, and adrenal gland, consistent with metastatic PAS. Given distant metastasis and inoperability, the patient received palliative chemotherapy. PAS frequently resembles thromboembolic disease. Lack of response to anticoagulation, persistent vascular filling defects, extraluminal extension, and FDG uptake on PET-CT are important clues favoring PAS. Histopathological confirmation remains essential for definitive diagnosis. Early recognition is critical, as delayed diagnosis is associated with significantly increased mortality. Management includes surgery, chemotherapy, and radiotherapy, though prognosis remains poor in advanced disease. Increased clinical awareness may facilitate earlier detection and improved management of this rare but lethal entity.
Keywords
pulmonary artery sarcoma - pulmonary - sarcoma - embolism - pulmonary sarcoma - pulmonary embolismPublication History
Received: 23 November 2025
Accepted: 05 January 2026
Article published online:
22 January 2026
© 2026. International College of Angiology. This article is published by Thieme.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Qin J, Ng CS, He P, Lin X, Lin X, Hou P. Pulmonary artery intimal sarcoma - A primeval or rediscovered tumor? A report of 14 new cases with literature review. Pathol Res Pract 2021; 224: 153548
- 2 Bode-Lesniewska B, Zhao J, Speel EJ. et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch 2001; 438 (01) 57-65
- 3 Srivali N, Yi ES, Ryu JH. Pulmonary artery sarcoma mimicking pulmonary embolism: a case series. QJM 2017; 110 (05) 283-286
- 4 Manso L, Alvarez E, Quintela M, Cortes-Funes H, Hitt R. Primary pulmonary artery sarcoma: report of three cases and review of the literature. Clin Lung Cancer 2007; 8 (04) 277-281
- 5 Bandyopadhyay D, Panchabhai TS, Bajaj NS, Patil PD, Bunte MC. Primary pulmonary artery sarcoma: a close associate of pulmonary embolism-20-year observational analysis. J Thorac Dis 2016; 8 (09) 2592-2601
- 6 Gan HL, Zhang JQ, Huang XY, Yu W. The wall eclipsing sign on pulmonary artery computed tomography angiography is pathognomonic for pulmonary artery sarcoma. PLoS One 2013; 8 (12) e83200
- 7 Wyler von Ballmoos MC, Chan EY, Reardon MJ. Imaging and surgical treatment of primary pulmonary artery sarcoma. Int J Cardiovasc Imaging 2019; 35 (08) 1429-1433
- 8 Harbhajanka A, Dahoud W, Michael CW, Elliot R. Cytohistological correlation, immunohistochemistry and murine double minute clone 2 amplification of pulmonary artery intimal sarcoma: a case report with review of literature. Diagn Cytopathol 2019; 47 (05) 494-497
- 9 Yin K, Zhang Z, Luo R. et al. Clinical features and surgical outcomes of pulmonary artery sarcoma. J Thorac Cardiovasc Surg 2018; 155 (03) 1109-1115.e1
- 10 Hsu JY, Seligson ND, Hays JL, Miles WO, Chen JL. Clinical utility of CDK4/6 inhibitors in sarcoma: successes and future challenges. JCO Precis Oncol 2022; 6: e2100211